Quarterly report pursuant to Section 13 or 15(d)

Collaboration Agreement - Additional Information (Detail)

v2.4.0.8
Collaboration Agreement - Additional Information (Detail) (USD $)
3 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Dec. 31, 2013
Mar. 31, 2014
Teva Pharmaceutical Industries Ltd. [Member]
Mar. 31, 2014
Isis Pharmaceuticals Inc. and University of British Columbia [Member]
Dec. 31, 2009
Collaboration arrangement [Member]
Teva Pharmaceutical Industries Ltd. [Member]
Mar. 31, 2014
Collaboration arrangement [Member]
Teva Pharmaceutical Industries Ltd. [Member]
Mar. 31, 2013
Collaboration arrangement [Member]
Teva Pharmaceutical Industries Ltd. [Member]
Mar. 31, 2014
Collaboration arrangement [Member]
Teva Pharmaceutical Industries Ltd. [Member]
Minimum [Member]
Mar. 31, 2014
Collaboration arrangement [Member]
Teva Pharmaceutical Industries Ltd. [Member]
Maximum [Member]
Dec. 31, 2009
Collaboration arrangement [Member]
Isis Pharmaceuticals Inc. [Member]
Mar. 31, 2014
Collaboration arrangement [Member]
Isis Pharmaceuticals Inc. [Member]
Dec. 31, 2009
Collaboration arrangement [Member]
Isis Pharmaceuticals Inc. and University of British Columbia [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Collaboration agreement aggregate amount           $ 50,000,000              
Maximum amount receivable           370,000,000              
Equity investment             10,000,000            
Royalties at percentage rates ranging             Mid-teens to mid-twenties on net sales            
Share premium             20.00%            
Common shares, purchase price             $ 37.38            
Common shares purchased             267,531            
Average premium period             30 days            
Research and development 16,903,000 10,855,000                 10,000,000   300,000
Percentage of milestone payments required to be paid to third party             31.00%            
Percentage of net sales required to be paid as royalty to third party                 4.88% 8.00%      
Direct and indirect costs incurred             30,000,000            
Required period of notice for termination of Collaboration agreement                 3 months 6 months      
Expiration of royalties             10 years            
Period of authorization change             90 days            
Revenue 11,731,000 5,076,000         11,731,000 5,076,000          
Amounts receivable 8,610,000   8,657,000 8,610,000                  
Receivable for unbilled expense reimbursements       7,600,000                  
Milestone payment due         20,000,000             20,000,000  
Period of milestone payment         21 days             21 days  
Reserve for contingency of non payment of non-royalty milestone amount         20,000,000             20,000,000  
Milestone payment made         10,000,000             10,000,000  
Balance amount of milestone payment         10,000,000             10,000,000  
Balance in advanced reimbursement of development activities         $ 30,000,000